The results from the ongoing randomized controlled phase III study evaluating T-DXd in combination with pembrolizumab chemotherapy in first-line therapy (DESTINY-Lung 04) (Bob et al. 2022), and the exploratory phase I studies evaluating ADCs in combination with ICIs in previously treated patients (NCT04686305, NCT04042701, NCT05482568) may provide valuable insights for improving the treatment outlook for patients with HER2-mutated advanced NSCLC treated with ICIs in combination(Y. Yu et al. 2023). Here, ERBB2 is linked to non-small cell lung carcinoma.